148505-45-7 Usage
General Description
4-(4'-Nitrophenoxy)piperidine hydrochloride is a chemical compound that is a derivative of piperidine. It is a white to off-white powder, soluble in water and ethanol. 4-(4'-NITROPHENOXY)PIPERIDINE HYDROCHLORIDE can be used as an intermediate in the synthesis of pharmaceuticals, agrochemicals and other organic compounds. It has a variety of potential applications such as in the pharmaceutical industry for the preparation of certain drugs. It should be handled and stored according to proper safety precautions due to its potential health hazards and should only be used by qualified individuals in a controlled laboratory environment.
Check Digit Verification of cas no
The CAS Registry Mumber 148505-45-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,5,0 and 5 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 148505-45:
(8*1)+(7*4)+(6*8)+(5*5)+(4*0)+(3*5)+(2*4)+(1*5)=137
137 % 10 = 7
So 148505-45-7 is a valid CAS Registry Number.
148505-45-7Relevant articles and documents
COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
-
Paragraph 0358; 0361, (2020/04/24)
The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.
Sulfamato hydroxamic acid metalloprotease inhibitor
-
, (2008/06/13)
A sulfamato hydroxamic acid compound that, inter alia, inhibits matrix metalloprotease (mmp) activity is disclosed as are a process for preparing the same, intermediate compounds useful in those syntheses, and a treatment process that comprises administering a contemplated sulfamato hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
